Blyngju G John: growth and investment in 2018

Highlights 1 Research pipeline filling in the fields of tumor, fibrotic disease, immune and metabolic disease 2 The business growth of all businesses has exceeded the market average 3 The animal health business acquired in 2017 successfully completed the integration of technology level April 17, 2019 / American news agency / -- Research and development driven pharmaceutical company bolingyin Gehan today announced that the net sales in 2018 will be 17.5 billion euros Excluding the exchange rate impact and the one-off impact of the swap with Sanofi in 2017, net sales increased by 4% Total R & D expenditure reached 3.2 billion euros (+ 2.8%), accounting for 18.1% of annual sales Over the past year, the company has focused on specific treatment areas "We want to make a significant contribution to better cancer treatment," said hubertusvon Baumbach, chairman of the Executive Board of Boehringer Ingelheim At the same time, we are also engaged in the research of fibrotic diseases, metabolic diseases and immune diseases We have a very strong pipeline of products under research " The company's investment in tangible assets reached nearly 1 billion euros (+ 9%), a record high Operating revenue again reached EUR 3.5bn (- 0.4%), and the group's profit after tax increased to EUR 2.1bn "In 2018, our return on net sales increased from 19.3% to 19.8%, and our equity ratio increased from nearly 38% to 40%, said Michael schmelmer, the company's financial director and executive board member Therefore, from a financial point of view, we are also a very healthy company " The average number of employees in all regions increased slightly to 50370 (+ 2%) Human drugs business - a strong product portfolio in 2018, the human drugs business's net sales reached 12.6 billion euros, accounting for 72% of the company's total net sales Despite the predictable decline in net sales due to the expiration of innovative drug patents, the overall business of human drugs still achieved strong growth, with the exchange rate adjusted net sales up 5.1% Revenue from the global authorised business was lower than in the previous year, bringing the overall growth rate of the business to 3.3% As in previous years, Spiriva ® still has the highest net sales of EUR 2.4 billion (exchange rate adjusted - 11.4%) Secondly, the net sales of the jardiance family (including synjardy and glyxambi) of type 2 diabetes drugs reached 1.8 billion euros (52.53% after exchange rate adjustment) The net sales of the anticoagulant, pradaxa ®, amounted to 1.5 billion euros (+ 7.0% after exchange rate adjustment) The net sales of the type 2 diabetes drug, trajenta ®, amounted to 1.4 billion euros (+ 9.0% after exchange rate adjustment) The net sales of ovev, a drug for the treatment of idiopathic pulmonary fibrosis (IPF), reached 1.1 billion euros (exchange rate adjusted + 28.7%) The R & D investment in the field of human drugs reached 2.8 billion euros, equivalent to 22.1% of the net sales of human drugs Bringer ingelham has 90 R & D projects in various stages The company's goal is to make 75% of its projects the first of its kind or the first in a new field of treatment in the relevant active ingredient category In the field of cancer, the company focuses on lung cancer, gastric cancer and colorectal cancer In the field of fibrosis, the company focuses on systemic scleroderma related interstitial lung disease In the field of metabolic diseases, the company's main research focus is non-alcoholic fatty liver In immunology, the company focuses on chronic inflammatory diseases of the skin and intestines In addition, Boehringer Ingelheim is also carrying out research and development projects in other diseases, including central nervous system diseases (such as Alzheimer's disease and schizophrenia), obesity and retinopathy Animal health business - technical level integration completed in the field of animal health business, Boehringer Ingelheim focuses on innovative vaccines and insecticides, and provides further treatment programs for livestock and pets In 2018, nexgard, frontline, Heartgard and ingelvaccircoflex are the four best-selling products Net sales of the animal health business amounted to EUR 4 billion, accounting for 23% of the group's total net sales In the second year after the completion of the Meria deal, the net sales of the animal health business increased significantly, reaching 5.6% after the exchange rate adjustment At the same time, business integration went smoothly "From the first day of integration, we have been committed to ensuring a continuous supply of products to our customers," Mr Feng said As a result, we have achieved good growth and the integration of technology has been successfully completed " In the field of animal health care, those innovative potentials that are related to the research and development of human drugs deserve special attention Biopharmaceutical contract production maintained a leading position in fy2018, and biopharmaceutical business maintained its leading position in contract production, with net sales accounting for 4% of the group's total net sales Orders keep a positive growth trend, making full use of biopharmaceutical production capacity Looking forward to this financial year in 2019, bringer Ingelheim expects a slight increase in net sales compared to the same period, while the investment projects will also accelerate development "In Europe alone, we plan to invest more than 3 billion euros over the next five years," Mr Fung said In this regard, the key premise is that our European factory has strong comprehensive competitiveness " About the R & D driven pharmaceutical company, Brigitte Ingelheim has always been committed to improving human and animal health, focusing on the exploration of disease areas where no effective treatment has yet emerged The company focuses on developing innovative therapies to help patients extend their lives In the field of animal health, Boehringer Ingelheim represents an advanced prevention program Founded in 1885, Boehringer Ingelheim is still a family business The company is one of the top 20 pharmaceutical companies in the world In the three business areas of human medicine, animal health and biopharmaceutical contract production, about 50000 employees around the world are striving to show value through innovation every day In 2018, Boehringer Ingelheim achieved a net sales of about 17.5 billion euros; research and development expenditure was nearly 3.2 billion euros, equivalent to 18.1% of the net sales As a family business, Boehringer Ingelheim is ambitious and committed to long-term success The company aims to achieve organic growth through its own resources, while actively seeking partners and strategic alliances in the field of R & D In addition, all actions of the company are responsible for human beings and the environment Source: Boehringer Ingelheim